I. 
CALL TO ORDER AND INTRODUCTORY REMARKS: 
Dr. McGarrity, Chair, called the meeting of the Recombinant DNA 
Advisory Committee (RAC) of the National Institutes of Health 
(NIH) to order at 9:00 a.m., October 3, 1988. The meeting was 
called pursuant to a Federal Register notice that, being 30 or 
more days prior to today's date, met requirements published in 
the NIH Guidelines for Research Involving Recombinant DNA 
Molecules. He stated that the meeting would remain open to the 
public for its entirety, and that he expected the meeting to 
conclude within one day. 
Dr. McGarrity asked Dr. Gartland if a quorum was present and 
Dr. Gartland assured the Chair that a quorum was in attendance. 
Dr. McGarrity noted that he intended to make every effort to 
abide by the distributed agenda with respect to time estimates 
for each item of business. He reminded the Committee that in 
recognizing persons for comments he would use the following 
order: primary and secondary reviewers on each item as set forth 
in the agenda; other members of RAC; ad hoc consultants to the 
RAC; NIH staff members; members of the public who had submitted 
written comments; and finally, other members of the public. He 
underlined that RAC was advisory to the Director of NIH; and in 
light of this, persons with minority opinions should voice them 
so as to provide Dr. Wyngaarden with the entire spectrum of 
opinions on a given topic. Dr. McGarrity then told the Committee 
that in all voting he would call first for the affirmative, then 
for the negative, and finally for abstentions. He emphasized 
that if any voting member felt compelled to abstain due to 
conflict of interest, that such member should notify the Chair so 
that the record could duly reflect such. 
Dr. McGarrity then introduced the ad hoc consultants for the 
meeting: Dr. William Kelley, Chairman of the Department of 
Internal Medicine, University of Michigan Medical School; 
Mr. Robert Lanman, NIH Legal Advisor, Office of the General 
Counsel; and Dr. Robert McKinney, Director of the NIH Division of 
Safety. 
Dr. McGarrity then made note of Mailings I and II, which were 
sent to members prior to the meeting. He also noted that some 
recently received materials were supplied at the table for each 
member . 
Dr. McGarrity then introduced Dr. Jay Moskowitz, Associate 
Director for Science Policy and Legislation in the Office of the 
Director (OD) , NIH, the new Acting Executive Secretary of the 
Committee, for his introductory remarks. 
[230] 
Recombinant DNA Research, Volume 13 
